Robert Martell

Robert Martell, M.D., Ph.D.

Head of Research & Development

Dr. Martell is Head of Research & Development at Curis. From September 2011 to May 2018, Dr. Martell served on Curis’ Board of Directors. He is a co-founder of Epi-Cure Pharmaceuticals, a privately held early-stage biotechnology company, and served on its Board of Directors and as president from June 2016 to August 2018. Previously, Dr. Martell served as Chief Medical Officer at Tesaro, Inc., a biopharmaceutical company developing Zejula and Varubi. Dr. Martell currently serves as Attending Physician at Tufts Medical center, and over the past 10 years he has served various other roles there, and at Tufts University School of Medicine, including Director of the Neely Center for Clinical Cancer Research and Leader of the Cancer Center’s Program in Experimental Therapeutics. Prior to that, he served as Vice President and Chief Medical Officer of MethylGene, Director of Oncology Global Clinical Research at Bristol-Myers Squibb Company, and Deputy Director of the Medical Science Unit at Bayer Corporation developing Nexavar. During this time, he served concurrently as Assistant Clinical Professor of Oncology at Yale University School of Medicine. Dr. Martell earned a B.A. in Chemistry from Kalamazoo College, a Ph.D. in Pharmacology from the University of Michigan, and an M.D. from Wayne State University. Dr. Martell completed his internal medicine internship and residency and medical oncology fellowship at Duke University Medical Center.